Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept.
Metadatas
- doi: 10.1007/s00417-017-3762-2
- issn: 0721-832X
This document is linked to :
info:eu-repo/semantics/altIdentifier/doi/10.1007/s00417-017-3762-2
This document is linked to :
info:eu-repo/semantics/altIdentifier/pmid/28798980
This document is linked to :
info:eu-repo/semantics/altIdentifier/eissn/1435-702X
This document is linked to :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_4D5A562336216
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Similar subjects
TherapyCite this document
P. Parvin et al., « Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept. », Serveur académique Lausannois, ID : 10.1007/s00417-017-3762-2
Metrics
Share / Export
Abstract
The purpose of our study was to investigate the two-year outcome of Aflibercept treatment for neovascular age-related macular degeneration (nAMD), using the Observe-and-Plan regimen, an individually planned treatment regimen, based on the predictability of an individual's need for retreatment, aiming to reduce the clinical burden. Our prospective study used the Observe-and-Plan regimen with Aflibercept to treat nAMD: Three loading doses, followed by monthly observation visits until the disease-recurrence interval was determined, which then was shortened by 2 weeks in a treatment plan for the next three injections without intermediate monitoring visits. The subsequent treatment plans were adjusted according to periodically assessed disease activity. The primary outcome measures were visual acuity changes, number of injections, and number of monitoring visits. The study included 112 eyes of 102 patients with a mean age of 80.7 years (SD 7.6). Mean visual acuity (VA) improved from 61.8 ETDRS letters (20/60(+2)) at baseline, by 8.5, 8.0, and 6.2 letters at months 3, 12 and 24, respectively. Mean central retinal thickness was 438um at baseline, and reduced by 152um, 155um, and 150um at months 3, 12 and 24, respectively. The mean number of injections was 8.7 and 6.5 in the first and second year, respectively. The mean number of monitoring visits after baseline was 3.8 and 2.8 during the first and second year, respectively. The Observe-and-Plan regimen significantly improved VA, while fewer monitoring visits were needed as compared to other variable dosing regimens, thus reducing the workload for chronic care management of nAMD.
